Performance of preliminary cut-points for progression from mild cognitive impairment to dementia of the Alzheimer's disease type using fully automated chemiluminescent beta-amyloid 42 and tau assays

P2-072 PERFORMANCE OF PRELIMINARY CUT-POINTS FOR PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO DEMENTIA OF THE ALZHEIMER’S DISEASE TYPE USING FULLY AUTOMATED CHEMILUMINESCENT BETAAMYLOID 42 AND TAU ASSAYS Adam Simon, Salvatore Salamone, William Clarke, George Green, Holly Soares, Leah Burns, Irina Baburina, Daniel Kozo, Jodi Courtney, Paul Contestable, Shari Jackson, Patience Ajongwen, AJ Simon Enterprises LLC., Yardley, Pennsylvania, United States; Saladax Biomedical, Inc., Bethlehem, New Jersey, United States; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States; Bristol Myers Squibb, Princeton, New Jersey, United States; Bristol Myers Squibb, Wallingford, New Jersey, United States; Bristol-Myers Squibb, Wallingford, New Jersey, United States; Saladax Biomedical, Bethlehem, Pennsylvania, United States; Ortho Clinical Diagnostics, Rochester, New York, United States; Ortho Clinical Diagnostics, Rochester, New York, United States. Contact e-mail: ssalamone@saladax.com